FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC: Form 990, tax year 2024
View the entire original 990 at ProPublica ↗
- Organization
- FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC (EIN 52-1986675)
- Tax period
- 2024-01-01 to 2024-12-31
- Filed
- 2025-11-06
- IRS object ID
- 202543109349302334
- Schema version
- 2024v5.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2025-11-06T11:23:26+00:00 | ReturnTs |
| Tax Period End | 2024-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 440160260 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Forvis Mazars LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 120 E Palmetto Park Road Suite 403 | AddressLine1Txt |
| City | Boca Raton | CityNm |
| State Abbreviation | FL | StateAbbreviationCd |
| ZIP | 33432 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2024-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 521986675 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Foundation for the National Institutes of Health Inc | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | FOUN | BusinessNameControlTxt |
| Phone | 3014025311 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 11400 Rockville Pike 600 | AddressLine1Txt |
| City | North Bethesda | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 20852 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | Donald M Hill | PersonNm |
| Person Title | Chief Financial Officer | PersonTitleTxt |
| Phone | 3014025311 | PhoneNum |
| Signature | 2025-11-06 | SignatureDt |
| Discuss With Paid Preparer | Yes (true) | DiscussWithPaidPreparerInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IRS Responsible Prty Info Curr | Yes (true) | IRSResponsiblePrtyInfoCurrInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | April Arnold | PreparerPersonNm |
| PTIN | P01559426 | PTIN |
| Phone | 5612991820 | PhoneNum |
| Preparation | 2025-11-06 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2024 | TaxYr |
| Build TS | 2025-03-06 01:10:19Z | BuildTS |
Form 990 IRS990
Principal Ofcr Business Name PrincipalOfcrBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Donald M Hill | BusinessNameLine1Txt |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 11400 Rockville Pike 600 | AddressLine1Txt |
| City | North Bethesda | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 20852 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $432,563,566 | GrossReceiptsAmt |
| Group Return For Affiliates | false | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | http://www.fnih.org | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1996 | FormationYr |
| Legal Domicile State | MD | LegalDomicileStateCd |
| Activity Or Mission | SEE SCHEDULE O | ActivityOrMissionDesc |
| Voting Members Governing Body | 22 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 21 | VotingMembersIndependentCnt |
| Total Employee | 122 | TotalEmployeeCnt |
| Total Volunteers | 21 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| PY Contributions Grants | $56,092,197 | PYContributionsGrantsAmt |
| CY Contributions Grants | $71,750,648 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $50,000 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $50,000 | CYProgramServiceRevenueAmt |
| PY Investment Income | $4,762,392 | PYInvestmentIncomeAmt |
| CY Investment Income | $6,516,337 | CYInvestmentIncomeAmt |
| PY Other Revenue | $61,199 | PYOtherRevenueAmt |
| CY Other Revenue | $190,224 | CYOtherRevenueAmt |
| PY Total Revenue | $60,965,788 | PYTotalRevenueAmt |
| CY Total Revenue | $78,507,209 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $20,270,897 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $22,714,461 | CYGrantsAndSimilarPaidAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $16,465,315 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $19,849,946 | CYSalariesCompEmpBnftPaidAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $223,254 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $32,908,531 | PYOtherExpensesAmt |
| CY Other Expenses | $34,254,511 | CYOtherExpensesAmt |
| PY Total Expenses | $69,644,743 | PYTotalExpensesAmt |
| CY Total Expenses | $76,818,918 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$8,678,955 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $1,688,291 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $206,113,368 | TotalAssetsBOYAmt |
| Total Assets EOY | $214,056,526 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $12,576,790 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $15,192,964 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $193,536,578 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $198,863,562 | NetAssetsOrFundBalancesEOYAmt |
| Mission | TO CREATE AND LEAD ALLIANCES AND PUBLIC-PRIVATE PARTNERSHIPS THAT ADVANCE BREAKTHROUGH BIOMEDICAL DISCOVERIES AND IMPROVE THE QUALITY OF PEOPLE'S LIVES | MissionDesc |
| Significant New Program Srvc | false | SignificantNewProgramSrvcInd |
| Significant Change | false | SignificantChangeInd |
| Expense | $64,210,906 | ExpenseAmt |
| Grant | $22,057,896 | GrantAmt |
| Revenue | $50,000 | RevenueAmt |
| Desc | SEE SCHEDULE O, PROGRAM ONE, RESEARCH PROGRAMS | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $1,631,357 | ExpenseAmt |
| Grant | $656,565 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | SEE SCHEDULE O, PROGRAM TWO, AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Expenses | $65,842,263 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (true) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (true) | ScheduleBRequiredInd |
| Political Campaign Acty | false | PoliticalCampaignActyInd |
| Lobbying Activities | false | LobbyingActivitiesInd |
| Subject To Proxy Tax | false | SubjectToProxyTaxInd |
| Donor Advised Fund | Yes (true) | DonorAdvisedFundInd |
| Conservation Easements | false | ConservationEasementsInd |
| Collections Of Art | false | CollectionsOfArtInd |
| Credit Counseling | false | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | Yes (true) | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (true) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | false | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | false | ReportProgramRelatedInvstInd |
| Report Other Assets | false | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (true) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (true) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (true) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | false | ConsolidatedAuditFinclStmtInd |
| School Operating | false | SchoolOperatingInd |
| Foreign Office | false | ForeignOfficeInd |
| Foreign Activities | Yes (true) | ForeignActivitiesInd |
| More Than5000 K To Org | false | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | false | MoreThan5000KToIndividualsInd |
| Professional Fundraising | false | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (true) | FundraisingActivitiesInd |
| Gaming Activities | false | GamingActivitiesInd |
| Operate Hospital | false | OperateHospitalInd |
| Grants To Organizations | Yes (true) | GrantsToOrganizationsInd |
| Grants To Individuals | Yes (true) | GrantsToIndividualsInd |
| Schedule J Required | Yes (true) | ScheduleJRequiredInd |
| Tax Exempt Bonds | false | TaxExemptBondsInd |
| Escrow Account | false | EscrowAccountInd |
| On Behalf Of Issuer | false | OnBehalfOfIssuerInd |
| Engaged In Excess Benefit Trans | false | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | false | PYExcessBenefitTransInd |
| Loan Outstanding | false | LoanOutstandingInd |
| Grant To Related Person | false | GrantToRelatedPersonInd |
| Business Rln With Org Mem | false | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | false | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | false | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (true) | DeductibleNonCashContriInd |
| Deductible Art Contribution | false | DeductibleArtContributionInd |
| Terminate Operations | false | TerminateOperationsInd |
| Partial Liquidation | false | PartialLiquidationInd |
| Disregarded Entity | Yes (true) | DisregardedEntityInd |
| Related Entity | false | RelatedEntityInd |
| Related Organization Ctrl Ent | false | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | false | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | false | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | false | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (true) | ScheduleORequiredInd |
| IRP Document | 48 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (true) | BackupWthldComplianceInd |
| Employee | 122 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (true) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | false | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | false | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | false | TaxablePartyNotificationInd |
| Nondeductible Contributions | false | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (true) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (true) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | false | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | false | PayPremiumsPrsnlBnftCntrctInd |
| DAF Excess Business Holdings | false | DAFExcessBusinessHoldingsInd |
| Taxable Distributions | false | TaxableDistributionsInd |
| Distribution To Donor | false | DistributionToDonorInd |
| Indoor Tanning Services | false | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | false | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | false | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 22 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 21 | IndependentVotingMemberCnt |
| Family Or Business Rln | false | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | false | DelegationOfMgmtDutiesInd |
| Change To Org Documents | false | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | false | MembersOrStockholdersInd |
| Election Of Board Members | false | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | false | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (true) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (true) | MinutesOfCommitteesInd |
| Officer Mailing Address | false | OfficerMailingAddressInd |
| Local Chapters | false | LocalChaptersInd |
| Policies Reference Chapters | false | PoliciesReferenceChaptersInd |
| Form990 Provided To Gvrn Body | Yes (true) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (true) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (true) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (true) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (true) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (true) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (true) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (true) | CompensationProcessOtherInd |
| Investment In Joint Venture | false | InvestmentInJointVentureInd |
| Written Policy Or Procedure | false | WrittenPolicyOrProcedureInd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | HI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Donald M Hill | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 3014356246 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 11400 Rockville Pike 600 | AddressLine1Txt |
| City | North Bethesda | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 20852 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (33 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|
| Dr Julie L Gerberding | ||||||||
| Chief Executive Officer | 40.0 | Yes (X) | Yes (X) | $640,273 | $0 | $49,562 | ||
| Charles A Reinhart III | ||||||||
| Board Member | 2.0 | Yes (X) | $0 | $0 | $0 | |||
| Dr Charles A Sanders | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Dr Edison T Liu | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Dr Elias Zerhouni | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Dr Ellen V Sigal | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Dr Freda Lewis-Hall | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Dr Gilbert S Omenn | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Dr Jay Bradner | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Dr Judy Lansing Kovler | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Dr Paul Stoffels | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Dr Ronald L Krall | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Dr Solomon H Snyder | ||||||||
| Vice-Chairman | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Dr Steven M Paul | ||||||||
| Chairman | 2.0 | Yes (X) | $0 | $0 | $0 | |||
| James Weiss | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Mr Fred Seigel | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Mr James Down | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Mr Perry Steiner | ||||||||
| Board Member | 2.0 | Yes (X) | $0 | $0 | $0 | |||
| Mr Russell W Steenberg | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| Mrs William McCormick Blair Jr | ||||||||
| Secretary | 1.0 | Yes (X) | $0 | $0 | $0 | |||
| Ms Julie Bell Lindsay | ||||||||
| Treasurer | 2.0 | Yes (X) | $0 | $0 | $0 | |||
| Ms Nina Kjellson | ||||||||
| Board Member | 0.5 | Yes (X) | $0 | $0 | $0 | |||
| David Carmel | ||||||||
| Senior Vice President, Chief Growth and Innovation Officer | 40.0 | $451,716 | $0 | $49,562 | Yes (X) | |||
| Donald Hill | ||||||||
| Senior Vice President, Chief Financial Officer | 40.0 | $336,184 | $0 | $49,267 | Yes (X) | |||
| Joseph Menetski | ||||||||
| Senior Vice President, Chief Translational Science Officer | 40.0 | $388,734 | $0 | $46,512 | Yes (X) | |||
| Kevin Klock | ||||||||
| Senior Vice President, Chief Operating Officer and General Counsel | 40.0 | $321,510 | $0 | $45,977 | Yes (X) | |||
| Love Collins | ||||||||
| Vice President, Advancement | 40.0 | $182,550 | $0 | $24,199 | Yes (X) | |||
| Michael Santos | ||||||||
| Senior Vice President, Chief Population Health Science Officer | 40.0 | $392,350 | $0 | $36,416 | Yes (X) | |||
| Catherine Master | ||||||||
| Vice President, Deputy General Counsel | 40.0 | $238,984 | $0 | $41,018 | Yes (X) | |||
| Courtney Silverthorn | ||||||||
| Vice President, Strategic Alliances and Innovation | 40.0 | $261,804 | $0 | $29,966 | Yes (X) | |||
| Eva Coyne | ||||||||
| Vice President -Controller | 40.0 | $245,164 | $0 | $38,777 | Yes (X) | |||
| Stacey Adam | ||||||||
| Vice President, Science Partnerships | 40.0 | $281,317 | $0 | $31,193 | Yes (X) | |||
| Steven Hoffmann | ||||||||
| Vice President, Science Partnerships | 40.0 | $264,766 | $0 | $40,305 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $4,005,352 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $482,754 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 74 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | false | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (true) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | false | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt | Address Line2ContractorAddress/USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|
| Dana-Farber Cancer Institute | ||||||
| 450 Brookline Avenue | Boston | MA | 02215 | Transitional Science Research Collaboration | $1,761,570 | |
| SWOG CTI | ||||||
| 24 Frank Lloyd Wright Drive | Ann Arbor | MI | 48105 | Clinical Trial for Lung Map Project | $1,500,260 | PO Box 483 |
| The Regents of the University of CaliforniaSD | ||||||
| 9500 Gilman Drive | La Jolla | CA | 920930955 | NIMBLE and AMP CMD Research Collaboration | $1,406,374 | MC 0009 |
| Ruder Finn Inc | ||||||
| 425 E 53rd St | New York | NY | 10022 | Professional Services | $1,299,020 | |
| Discovery Life Sciences LLC | ||||||
| 900 Hudson Way | Huntsville | AL | 35806 | AMP PD Project Research Collaboration | $1,192,389 | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 46 | CntrctRcvdGreaterThan100KCnt |
| Fundraising | $361,000 | FundraisingAmt |
| Government Grants | $1,250,000 | GovernmentGrantsAmt |
| All Other Contributions | $70,139,648 | AllOtherContributionsAmt |
| Noncash Contributions | $3,568,243 | NoncashContributionsAmt |
| Total Contributions | $71,750,648 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | Administrative Revenue | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $50,000 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $50,000 | RelatedOrExemptFuncIncomeAmt |
Total Oth Program Service Rev TotalOthProgramServiceRevGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $0 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $50,000 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $5,005,462 | TotalRevenueColumnAmt |
| Exclusion | $5,005,462 | ExclusionAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $0 | RealAmt |
| Personal | $0 | PersonalAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $354,996,860 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $353,485,985 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $1,510,875 | SecuritiesAmt |
| Other | $0 | OtherAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,510,875 | TotalRevenueColumnAmt |
| Exclusion | $1,510,875 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $760,596 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $361,000 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $570,372 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $190,224 | TotalRevenueColumnAmt |
| Exclusion | $190,224 | ExclusionAmt |
Miscellaneous Revenue MiscellaneousRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $0 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $0 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $78,507,209 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $50,000 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $6,706,561 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $21,813,761 | TotalAmt |
| Program Services | $21,813,761 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $900,700 | TotalAmt |
| Program Services | $900,700 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,014,812 | TotalAmt |
| Program Services | $878,711 | ProgramServicesAmt |
| Management And General | $2,136,101 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $12,431,054 | TotalAmt |
| Program Services | $8,511,158 | ProgramServicesAmt |
| Management And General | $3,884,270 | ManagementAndGeneralAmt |
| Fundraising | $35,626 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,045,925 | TotalAmt |
| Program Services | $617,456 | ProgramServicesAmt |
| Management And General | $412,395 | ManagementAndGeneralAmt |
| Fundraising | $16,074 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,250,867 | TotalAmt |
| Program Services | $1,447,651 | ProgramServicesAmt |
| Management And General | $758,376 | ManagementAndGeneralAmt |
| Fundraising | $44,840 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,107,288 | TotalAmt |
| Program Services | $628,942 | ProgramServicesAmt |
| Management And General | $460,317 | ManagementAndGeneralAmt |
| Fundraising | $18,029 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $266,563 | TotalAmt |
| Management And General | $266,563 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $125,628 | TotalAmt |
| Management And General | $125,628 | ManagementAndGeneralAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $236,721 | TotalAmt |
| Management And General | $236,721 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,029,577 | TotalAmt |
| Program Services | $3,308,966 | ProgramServicesAmt |
| Management And General | $712,172 | ManagementAndGeneralAmt |
| Fundraising | $8,439 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $41,120 | TotalAmt |
| Program Services | $36,558 | ProgramServicesAmt |
| Management And General | $4,353 | ManagementAndGeneralAmt |
| Fundraising | $209 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $60,492 | TotalAmt |
| Program Services | $30,533 | ProgramServicesAmt |
| Management And General | $29,834 | ManagementAndGeneralAmt |
| Fundraising | $125 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $271,180 | TotalAmt |
| Program Services | $116,972 | ProgramServicesAmt |
| Management And General | $138,133 | ManagementAndGeneralAmt |
| Fundraising | $16,075 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $737,279 | TotalAmt |
| Program Services | $181,564 | ProgramServicesAmt |
| Management And General | $555,715 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,110,676 | TotalAmt |
| Program Services | $2,690,383 | ProgramServicesAmt |
| Management And General | $340,593 | ManagementAndGeneralAmt |
| Fundraising | $79,700 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $571,210 | TotalAmt |
| Program Services | $502,890 | ProgramServicesAmt |
| Management And General | $67,876 | ManagementAndGeneralAmt |
| Fundraising | $444 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $233,505 | TotalAmt |
| Management And General | $233,505 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $242,768 | TotalAmt |
| Program Services | $131,491 | ProgramServicesAmt |
| Management And General | $111,277 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|---|
| Program Contracts | $23,726,622 | $23,726,622 | |
| Recruiting | $184,466 | $97,138 | $87,328 |
| Bad Debt Expense | $100,000 | $100,000 | |
| Equipment Rental and Maintenance | $74,547 | $6,762 | $67,785 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $242,157 | TotalAmt |
| Program Services | $114,005 | ProgramServicesAmt |
| Management And General | $124,459 | ManagementAndGeneralAmt |
| Fundraising | $3,693 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $76,818,918 | TotalAmt |
| Program Services | $65,842,263 | ProgramServicesAmt |
| Management And General | $10,753,401 | ManagementAndGeneralAmt |
| Fundraising | $223,254 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| EOY | $3,466,426 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $33,349,260 | BOYAmt |
| EOY | $37,968,576 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $42,017,805 | BOYAmt |
| EOY | $44,187,096 | EOYAmt |
Receivables From Officers Etc ReceivablesFromOfficersEtcGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $366,589 | BOYAmt |
| EOY | $503,799 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $3,281,124 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $1,921,669 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,470,643 | BOYAmt |
| EOY | $1,359,455 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $120,900,511 | BOYAmt |
| EOY | $120,117,237 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Investments Program Related InvestmentsProgramRelatedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,008,560 | BOYAmt |
| EOY | $6,453,937 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $206,113,368 | BOYAmt |
| EOY | $214,056,526 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,105,123 | BOYAmt |
| EOY | $7,931,677 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $408,334 | BOYAmt |
| EOY | $0 | EOYAmt |
Loans From Officers Directors LoansFromOfficersDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,063,333 | BOYAmt |
| EOY | $7,261,287 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,576,790 | BOYAmt |
| EOY | $15,192,964 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $32,672,601 | BOYAmt |
| EOY | $38,503,375 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $160,863,977 | BOYAmt |
| EOY | $160,360,187 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $193,536,578 | BOYAmt |
| EOY | $198,863,562 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $206,113,368 | BOYAmt |
| EOY | $214,056,526 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | $1,688,291 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $2,983,892 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $654,801 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | false | AccountantCompileOrReviewInd |
| FS Audited | Yes (true) | FSAuditedInd |
| Audit Committee | Yes (true) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (true) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (true) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $98,343,956 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $105,993,785 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $68,998,263 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $56,092,197 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $71,750,648 | CurrentTaxYearAmt |
| Total | $401,178,849 | TotalAmt |
Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $98,343,956 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $105,993,785 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $68,998,263 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $56,092,197 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $71,750,648 | CurrentTaxYearAmt |
| Total | $401,178,849 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $119,793,612 | SubstantialContributorsTotAmt |
| Public Support Total170 | $281,385,237 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,722,957 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,346,882 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $2,204,173 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $4,421,167 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $5,005,462 | CurrentTaxYearAmt |
| Total | $14,700,641 | TotalAmt |
Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $0 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $0 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $0 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $0 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $760,596 | CurrentTaxYearAmt |
| Total | $760,596 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $416,640,086 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $200,000 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.67537 | PublicSupportCY170Pct |
| Public Support PY170 | 0.66084 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part VI Form990ScheduleAPartVIGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Schedule A, Part II, Line 10 Other Income | FormAndLineReferenceDesc |
| Explanation | DESCRIPTION - FUNDRAISING REVENUE, COLUMN A - , COLUMN B - , COLUMN C - , COLUMN D - , COLUMN E - 760596.0, COLUMN F - 760596.0; | ExplanationTxt |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule D IRS990ScheduleD
| Field | Value | IRS element (for citing) |
|---|---|---|
| Donor Advised Funds Held | 2 | DonorAdvisedFundsHeldCnt |
| Funds And Other Accounts Held | 0 | FundsAndOtherAccountsHeldCnt |
| Donor Advised Funds Contri | $280,087 | DonorAdvisedFundsContriAmt |
| Funds And Other Accounts Contri | $0 | FundsAndOtherAccountsContriAmt |
| Donor Advised Funds Grants | $735,196 | DonorAdvisedFundsGrantsAmt |
| Funds And Other Accounts Grants | $0 | FundsAndOtherAccountsGrantsAmt |
| Donor Advised Funds Vl EOY | $606,662 | DonorAdvisedFundsVlEOYAmt |
| Funds And Other Accounts Vl EOY | $0 | FundsAndOtherAccountsVlEOYAmt |
| Disclosed Org Leg Ctrl | Yes (true) | DisclosedOrgLegCtrlInd |
| Disclosed For Charitable Prps | Yes (true) | DisclosedForCharitablePrpsInd |
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $22,940,299 | BeginningYearBalanceAmt |
| Contributions | $4,517,789 | ContributionsAmt |
| Investment Earnings Or Losses | $594,281 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | $148,712 | AdministrativeExpensesAmt |
| End Year Balance | $27,903,657 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $20,829,215 | BeginningYearBalanceAmt |
| Contributions | $1,847,034 | ContributionsAmt |
| Investment Earnings Or Losses | $523,194 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | $259,144 | AdministrativeExpensesAmt |
| End Year Balance | $22,940,299 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $24,511,134 | BeginningYearBalanceAmt |
| Contributions | -$85,775 | ContributionsAmt |
| Investment Earnings Or Losses | -$788,802 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | $2,807,342 | AdministrativeExpensesAmt |
| End Year Balance | $20,829,215 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $20,878,035 | BeginningYearBalanceAmt |
| Contributions | $3,154,350 | ContributionsAmt |
| Investment Earnings Or Losses | $544,664 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | $65,915 | AdministrativeExpensesAmt |
| End Year Balance | $24,511,134 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $14,897,505 | BeginningYearBalanceAmt |
| Contributions | $5,648,998 | ContributionsAmt |
| Investment Earnings Or Losses | $419,982 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | $88,450 | AdministrativeExpensesAmt |
| End Year Balance | $20,878,035 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated Balance EOY | 0.7144 | BoardDesignatedBalanceEOYPct |
| Prmnnt Endowment Balance EOY | 0.2856 | PrmnntEndowmentBalanceEOYPct |
| Term Endowment Balance EOY | 0.0 | TermEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | false | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | false | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $1,869,159 | OtherCostOrOtherBasisAmt |
| Depreciation | $850,569 | DepreciationAmt |
| Book Value | $1,018,590 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $1,411,965 | OtherCostOrOtherBasisAmt |
| Depreciation | $1,071,100 | DepreciationAmt |
| Book Value | $340,865 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $1,359,455 | TotalBookValueLandBuildingsAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp (3 entries)
| DescDesc | AmtAmt |
|---|---|
| Federal Income Taxes | |
| Charitable Gift Annuity | $103,001 |
| Operating Lease Liability | $7,158,286 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $7,261,287 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $82,158,766 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | $2,983,892 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $334,014 | DonatedServicesAndUseFcltsAmt |
| Other Revenue | $0 | OtherRevenueAmt |
| Revenue Not Reported | $3,317,906 | RevenueNotReportedAmt |
| Revenue Subtotal | $78,840,860 | RevenueSubtotalAmt |
| Investment Expenses Not Incld | $236,721 | InvestmentExpensesNotIncldAmt |
| Other Revenues Not Included | -$570,372 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | -$333,651 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $78,507,209 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $76,831,782 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $334,014 | DonatedServicesUseFcltsAmt |
| Other Expenses Included | -$84,429 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $249,585 | ExpensesNotReportedAmt |
| Expenses Subtotal | $76,582,197 | ExpensesSubtotalAmt |
| Investment Expenses Not Incld2 | $236,721 | InvestmentExpensesNotIncld2Amt |
| Other Expenses Not Included | $0 | OtherExpensesNotIncludedAmt |
| Expenses Not Rpt Fincl Stmt | $236,721 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $76,818,918 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (4 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Schedule D, Part V, Line 4 Intended uses of endowment funds | The Foundation has one endowment that is funded by multiple donors to seed new discoveries and/or be available to respond to epidemics and Foundation's unanticipated needs. The Foundation's other endowments consist of individual donor-restricted endowment funds established for a variety of purpose. (e.g. variety of research and educational initiatives at the Foundation for the NIH, Inc). Net assets associated with endowment funds are classified and reported based on the existence or absence or donor-imposed restrictions. |
| Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote | The Foundation is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code; accordingly, the accompanying financial statements do not reflect a provision or liability for federal and state income taxes. The Foundation has determined that it does not have any material unrecognized tax benefits or obligations as of December 31, 2024 and 2023. |
| Schedule D, Part XI, Line 4(b) Other revenues in form 990 not in audited financial statements | Fundraising Event Expenses - -570372 |
| Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990 | Fundraising Event Expenses - 570372 Refund of Prior Year Grants - -654801 |
Schedule F IRS990ScheduleF
Account Activities Outside US AccountActivitiesOutsideUSGrp (3 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| East Asia and the Pacific | 0 | 0 | Program Services | RESEARCH | $155,551 |
| Sub-Saharan Africa | 0 | 0 | Program Services | EDUCATION & TRAINING | $1,034,777 |
| Europe (Including Iceland and Greenland) | 0 | 0 | Program Services | RESEARCH | $1,542,714 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $2,733,042 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $2,733,042 | TotalSpentAmt |
| Transfer To Foreign Corp | false | TransferToForeignCorpInd |
| Interest In Foreign Trust | false | InterestInForeignTrustInd |
| Foreign Corp Ownership | false | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | false | PassiveForeignInvestmestCoInd |
| Foreign Partnership | false | ForeignPartnershipInd |
| Boycott Countries | false | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements | FormAndLineReferenceDesc |
| Explanation | EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; SUB-SAHARAN AFRICA-Accrual | ExplanationTxt |
Schedule G IRS990ScheduleG
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | FNIH Award Ceremony | Event1Nm |
| Gross Receipts Event1 | $1,121,596 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $361,000 | CharitableContriEvent1Amt |
| Gross Revenue Event1 | $760,596 | GrossRevenueEvent1Amt |
| Food And Beverage Event1 | $48,824 | FoodAndBeverageEvent1Amt |
| Other Direct Expenses Event1 | $521,548 | OtherDirectExpensesEvent1Amt |
| Gross Revenue Event2 | $0 | GrossRevenueEvent2Amt |
| Gross Receipts Other Events | $0 | GrossReceiptsOtherEventsAmt |
| Charitable Contri Other Events | $0 | CharitableContriOtherEventsAmt |
| Gross Revenue Other Events | $0 | GrossRevenueOtherEventsAmt |
| Gross Receipts Total | $1,121,596 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $361,000 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $760,596 | GrossRevenueTotalEventsAmt |
| Food And Beverage Total Events | $48,824 | FoodAndBeverageTotalEventsAmt |
| Oth Direct Expnss Total Events | $521,548 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $570,372 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | $190,224 | NetIncomeSummaryAmt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (21 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|
| NIH NIA | ||||||||
| 9000 Rockville Pike | Bethesda | MD | 20892 | 520858115 | 170(C)(1) GOVT UNIT | $18,000 | Research | |
| NIHNCI | ||||||||
| 9000 Rockville Pike | Bethesda | MD | 20892 | 520858115 | 170(C)(1) GOVT UNIT | $3,724,778 | Research | |
| NIHNIAID | ||||||||
| 9000 Rockville Pike | Bethesda | MD | 20892 | 520858115 | 170(C)(1) GOVT UNIT | $1,834,488 | Research | |
| NIHNIAMS | ||||||||
| 9000 Rockville Pike | Bethesda | MD | 20892 | 520858115 | 170(C)(1) GOVT UNIT | $8,700,000 | Research | |
| NIHNINDS | ||||||||
| 9000 Rockville Pike | Bethesda | MD | 20892 | 520858115 | 170(C)(1) GOVT UNIT | $614,100 | Research | |
| NIH NHLBI | ||||||||
| 9000 Rockville Pike | Bethesda | MD | 20892 | 520858115 | 170(C)(1) GOVT UNIT | $512,204 | Research | |
| NIHOD | ||||||||
| 9000 Rockville Pike | Bethesda | MD | 20892 | 520858115 | 170(C)(1) GOVT UNIT | $249,500 | Research | |
| NIH NIMH | ||||||||
| 9000 Rockville Pike | Bethesda | MD | 20892 | 520858115 | 170(C)(1) GOVT UNIT | $2,614,331 | Research | |
| NIHNEI | ||||||||
| 9000 Rockville Pike | Bethesda | MD | 20892 | 520858115 | 170(C)(1) GOVT UNIT | $31,500 | Research | |
| Research Triangle Institute | ||||||||
| PO Box 900002 | Raleigh | NC | 27675 | 560686338 | 501(c)(3) | $836,038 | Research | |
| University of Alabama at Birmingham | ||||||||
| Dept of Pediatric Admin Lowder Bl | Birmingham | AL | 352331711 | 636001138 | 501(c)(3) | $304,475 | Research | 1600 7th Avenue South |
| Thomas Jefferson University | ||||||||
| 125 South 9th Street | Philadelphia | PA | 19107 | 231352651 | 501(c)(3) | $736,764 | Research | 2nd Floor Sheridan Building |
| University of North Carolina Chapel Hill | ||||||||
| 104 Airport Drive | Chapel Hill | NC | 27599 | 800543561 | 501(c)(3) | $215,635 | Research | Suite 2200 Campus Box 1350 |
| University of Virginia | ||||||||
| PO Box 400195 | Charlottesville | VA | 229044195 | 546001796 | 501(c)(3) | $119,034 | Research | |
| University of Colorado Denver | ||||||||
| PO Box 910238 | Denver | CO | 80291 | 846000555 | 501(c)(3) | $15,091 | Research | |
| Duke University - Human Vaccine Institiute | ||||||||
| 200 West Main Street | Durham | NC | 27705 | 560532129 | 501(c)(3) | $79,647 | Research | Suite 820 Erwin Square Plaza |
| Fred Hutchinson Cancer Research Center | ||||||||
| 1100 Fairview Ave N | Seattle | WA | 98109 | 237156071 | 501(c)(3) | $562,536 | Research | |
| Trustees of Boston University | ||||||||
| 85 East Newton Street M-921 | Boston | MA | 02118 | 042103547 | 501(c)(3) | $231,516 | Research | |
| Friends of Cancer Research | ||||||||
| 1800 M Street NW Suite 1050 South | Washington | DC | 20036 | 521983273 | 501(c)(3) | $138,296 | Research | |
| Leidos Biomedical Research Inc | ||||||||
| 1050 Boyles Street | Frederick | MD | 21702 | 330653185 | $127,477 | Research | ||
| The Trustees of Columbia University | ||||||||
| PO Box 29789 | New York | NY | 100879789 | 135598093 | 501(c)(3) | $148,351 | RESEARCH | General Post Office |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 20 | Total501c3OrgCnt |
| Total Other Org | 1 | TotalOtherOrgCnt |
Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Type | Awards | GrantTypeTxt |
| Recipient | 26 | RecipientCnt |
| Cash Grant | $900,700 | CashGrantAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds | FormAndLineReferenceDesc |
| Explanation | Program and grants management staff invest considerable effort in providing scientific, administrative, and fiscal oversight for FNIH grants. Scientific and technical progress is monitored through semi-annual and annual reports from the grantees as well as through direct contact with investigators both by teleconference and site visits, and follow up to progress reports and site visits where scientific questions or administrative issues are identified. Scientific report submissions cover a wide range of items including individual objectives and overall progress review, milestone achievement, project plan update, and any other significant changes. Financial reporting is required annually for all of the grantees, and semi-annually for institutions that require additional oversight, such as for-profit institutions. Due diligence procedures, such as FNIH compliance with the USA Patriot Act and IRS requirements on expenditure responsibilities, have been incorporated into the reporting process to ensure that the grantees are complying with grant, legal, financial, and regulatory requirements. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Written Employment Contract | Yes (X) | WrittenEmploymentContractInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | false | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | false | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | false | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | false | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | false | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | false | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | false | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | false | AnyNonFixedPaymentsInd |
| Initial Contract Exception | false | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (12 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dr Julie L Gerberding | ||||||||||||||
| Chief Executive Officer | $532,225 | $0 | $105,000 | $0 | $3,048 | $0 | $27,600 | $0 | $21,962 | $0 | $689,835 | $0 | $0 | $0 |
| Donald Hill | ||||||||||||||
| Senior Vice President, Chief Financial Officer | $314,600 | $0 | $20,000 | $0 | $1,584 | $0 | $27,305 | $0 | $21,962 | $0 | $385,451 | $0 | $0 | $0 |
| David Carmel | ||||||||||||||
| Senior Vice President, Chief Growth and Innovation Officer | $428,300 | $0 | $20,000 | $0 | $3,416 | $0 | $27,600 | $0 | $21,962 | $0 | $501,278 | $0 | $0 | $0 |
| Joseph Menetski | ||||||||||||||
| Senior Vice President, Chief Translational Science Officer | $367,150 | $0 | $20,000 | $0 | $1,584 | $0 | $27,600 | $0 | $18,912 | $0 | $435,246 | $0 | $0 | $0 |
| Kevin Klock | ||||||||||||||
| Senior Vice President, Chief Operating Officer and General Counsel | $301,150 | $0 | $20,000 | $0 | $360 | $0 | $26,065 | $0 | $19,912 | $0 | $367,487 | $0 | $0 | $0 |
| Michael Santos | ||||||||||||||
| Senior Vice President, Chief Population Health Science Officer | $371,990 | $0 | $20,000 | $0 | $360 | $0 | $27,600 | $0 | $8,816 | $0 | $428,766 | $0 | $0 | $0 |
| Love Collins | ||||||||||||||
| Vice President, Advancement | $179,460 | $0 | $0 | $0 | $3,090 | $0 | $14,554 | $0 | $9,645 | $0 | $206,749 | $0 | $0 | $0 |
| Courtney Silverthorn | ||||||||||||||
| Vice President, Strategic Alliances and Innovation | $249,769 | $0 | $11,800 | $0 | $235 | $0 | $20,950 | $0 | $9,016 | $0 | $291,770 | $0 | $0 | $0 |
| Eva Coyne | ||||||||||||||
| Vice President -Controller | $235,650 | $0 | $9,000 | $0 | $514 | $0 | $19,865 | $0 | $18,912 | $0 | $283,941 | $0 | $0 | $0 |
| Stacey Adam | ||||||||||||||
| Vice President, Science Partnerships | $266,460 | $0 | $14,500 | $0 | $357 | $0 | $22,477 | $0 | $8,716 | $0 | $312,510 | $0 | $0 | $0 |
| Steven Hoffmann | ||||||||||||||
| Vice President, Science Partnerships | $250,750 | $0 | $12,500 | $0 | $1,516 | $0 | $21,393 | $0 | $18,912 | $0 | $305,071 | $0 | $0 | $0 |
| Catherine Master | ||||||||||||||
| Vice President, Deputy General Counsel | $228,709 | $0 | $7,500 | $0 | $2,775 | $0 | $19,406 | $0 | $21,612 | $0 | $280,002 | $0 | $0 | $0 |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contribution | 1 | ContributionCnt |
| Noncash Contributions Rpt F990 | $40,151 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | Market value | MethodOfDeterminingRevenuesTxt |
Drugs And Medical Supplies DrugsAndMedicalSuppliesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contribution | 12 | ContributionCnt |
| Noncash Contributions Rpt F990 | $3,478,095 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | Market value | MethodOfDeterminingRevenuesTxt |
Other Non Cash Contri Table OtherNonCashContriTableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Desc | Computers | Desc |
| Contribution | 1 | ContributionCnt |
| Noncash Contributions Rpt F990 | $49,997 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | Market value | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form8283 Received | 0 | Form8283ReceivedCnt |
| Any Property That Must Be Held | false | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | false | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | false | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Schedule M, Part I Explanations of reporting method for number of contributions | FormAndLineReferenceDesc |
| Explanation | Securities - Publicly traded - Number of Contributions Other - Computers Number of Contributions Drugs and medical supplies - Number of Contributions | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (11 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Form 990, Part I, Line 1 Brief Mission | To create and lead alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people's lives scientists at the National Institutes of Health (NIH) with their counterparts in life sciences companies, academia, patient organizations, foundations, and regulatory agencies (including the Food and Drug Administration and European Medicines Agency). Through team science, the FNIH solves complex health challenges and accelerates breakthroughs for patients, regardless of who they are or what health threats they face. The FNIH contributes to the development of new therapies, diagnostics, and potential cures; advances global health; and helps train the next generations of scientists. Established by Congress in 1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization. |
| Form 990, Part III, Line 4a Program Service Description | PROGRAM ONE - RESEARCH PROGRAMS - ACCELERATING MEDICINES PARTNERSHIP PROGRAM The FNIH manages the Accelerating Medicines Partnership (AMP) program with the interests of the collective scientific and medical research communities in mind. Its mission is to improve understanding of disease pathways, facilitate better selection of targets for treatment, and identify platforms and processes to accelerate new and effective therapies to patients. All AMP projects operate under the broad principle of delivering pre-competitive advancements to the research and medical fields and enabling the broadest possible access and use of AMP research discoveries. A critical component of each public-private partnership in the AMP program is an agreement among partners to make data and analyses arising from the collaboration publicly accessible to benefit the broader biomedical community. Individual AMP projects frequently establish public portals to rapidly disseminate data from their research efforts, and AMP-funded publications are required to be made available publicly within specific timeframes. At the center of the AMP program is a common goal of accelerating new and effective therapies to patients. AMP projects work towards this goal by identifying clinically relevant disease targets, improving identification of patients most likely to respond to a particular treatment, and safely reducing the development timelines for life-saving therapies and improvements in patient outcomes. The AMP program celebrated its 10-year anniversary in 2024 with a two-day symposium spotlighting the wide-ranging impact of the initiative. BIOMARKERS CONSORTIUM The Biomarkers Consortium (BC) creates and leads cross-sector efforts that validate and qualify biomarkers and other tools to accelerate better decision making for the development of new therapeutics and health technologies. It convenes government, industry, patients and patient advocacy groups, and not-for-profit organizations to address one of the most pressing needs in the diagnosis and treatment of disease: the development and the seeking of regulatory approval for disease biomarkers and surrogate endpoints. The BC is helping facilitate, catalyze, and support a new era of precision medicine by advancing biomarker science to enable earlier interventions, personalized treatments, and better outcomes in disease prevention, detection, diagnosis, and therapy. GENECONVENE GLOBAL COLLABORATIVE The GeneConvene Global Collaborative continues to advance best practices and support informed decision-making on the scientific, regulatory, and policy questions raised by the development of genetic biocontrol technologies to control the spread of malaria and other mosquito-borne diseases. GeneConvene convened in 2024 a working group of developers preparing for field trials to assess technologies for entomological monitoring and surveillance, hosting a webinar and meeting on environmental monitoring, and leading a Gene Drive Research Forum discussion of the opportunities for ecological modeling to further contribute to safety assessments. Through the African Genetic Biocontrol Consortium, the program also conducted two workshops for scientists and science communicators to build relationships and skills. GeneConvene also strengthened biosafety regulatory capacity through a training conducted with the African Union Development Agency-NEPAD and sponsored a course for 50 faculty and PhD-level scientists from African institutions on genome editing. RESEARCH PROGRAMS FOR ACCELERATING NEW THERAPIES RESEARCHING COVID TO ENHANCE RECOVERY-TREATING LONG COVID (RECOVER-TLC) RECOVER-TLC is a partnership between the NIH's National Institute of Allergy and Infectious Diseases and the FNIH, with the overarching goal to launch additional Long COVID clinical trials with promising agents. Therapeutic submissions were submitted to the online portal in 2024, and a process was created to enable uniform assessment of all submitted agents. These efforts initiated early working group formation, with the Antiviral Working Group conducting initial agent review by the end of 2024. NEW AMP PROJECTS AMP AMYOTROPHIC LATERAL SCLEROSIS (ALS) AMP ALS was launched in 2024 to expedite the identification of biomarkers and clinical outcome assessments that would allow earlier diagnosis and accelerated drug development for ALS, a progressive and ultimately fatal neurological disease. The project will create the largest data source for ALS research. AMP PARKINSON'S DISEASE AND RELATED DISORDERS (PDRD) AMP PDRD, launched in 2024, seeks to employ a data-driven approach to identify and validate biomarkers distinguishing Parkinson's disease from related diseases, with an overarching goal to enhance the success of clinical trials and ultimately broaden treatment options for individuals affected by these conditions. BIOMARKERS CONSORTIUM RESEARCH PROJECTS EARLY DETECTION OF ALZHEIMER'S DISEASE: PLASMA A Results of a Plasma A project study on early diagnosis of Alzheimer's disease were published last year. This head-to-head evaluation and cross-platform validation of biomarkers that most accurately detect amyloid plaques and other Alzheimer's-related pathologies revealed that the performance of some blood plasma tests were as good as cerebrospinal fluid tests. This finding suggested that simple blood tests could replace invasive spinal taps or costly brain scans for many patients. The study confirmed that blood tests are an accessible, less invasive, and highly accurate method of detecting amyloid plaques. The study offered further confirmation that blood tests measuring levels of the protein p-tau217 are the most accurate in determining the presence and amount of amyloid plaques. Alzheimer's blood tests could speed future drug development by helping researchers select the optimal participants for clinical trials. NEUROFILAMENT AS A BLOOD-BASED BIOMARKER OF NEURODEGENERATION IN FAMILIAL FTD The earliest stages of frontotemporal dementia (FTD) are hard to detect until the disease has progressed and damage is permanent. This project seeks to identify reliable blood tests to detect FTD and give access to disease-modifying clinical trials. The FDA accepted a Letter of Intent to qualify neurofilament (a key protein component of neurons) as a biological indicator of FTD in April 2024. This biomarker qualification initiative is crucial for improving the ability to identify individuals at high risk of progressing to clinical disease, as well as for advancing the development of a formal biomarker qualification plan to support future studies on neurofilament and its role in FTD. This progress lays the groundwork for enhancing early detection and accelerating research efforts in neurodegenerative diseases. IDENTIFYING RISK OF PROGRESSION TO MULTIPLE MYELOMA: MMYERISK Multiple myeloma, a cancer of plasma cells, is almost always preceded by asymptomatic, pre-malignant conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Although these precursor conditions are common, most patients do not progress to multiple myeloma. MMyeRisk, launched in 2024, seeks to identify which patients are likely to progress and identify those likely to benefit from early therapeutic intervention. The project team expects to achieve these aims through validation of blood-based genomic methods to define tumor and immune biomarkers. EVALUATING IMMUNOTHERAPY TREATMENT RESPONSE: IRELATE Despite the potential of immunotherapy, only a minority of patients respond to treatment. As effective immunotherapy treatments enhance T-cell infiltration and activation, understanding T-cell behavior is paramount for developing successful treatment strategies. Biopsies are used to assess T-cell states, but they are invasive and may not accurately reflect tumor burden. Positron emission tomography (PET) imaging holds promise as a non-invasive, comprehensive means for evaluating T-cell activity. The iRelate project aims to assess T-cell presence and activation state using two PET ligands in clinical development. Using both PET tracers will enable characterization of tracer uptake in tumor tissue and T cell-rich organs and is expected to provide information on unique and additive capacities of these tracers. This work is intended to serve as a foundation for defining potential context of use for PET biomarkers and to support the development and selection of successful immunotherapy treatment strategies. |
| Form 990, Part III, Line 4a Program Service Description | RESEARCH PROGRAMS FOR ADVANCING GLOBAL HEALTH A-PLUS: ANTIBIOTIC PROVES COST EFFECTIVE IN REDUCING MATERNAL INFECTIONS A 2023 international trial, supported in part by the FNIH, revealed that one dose of the oral antibiotic azithromycin during labor can greatly reduce maternal sepsis or death in low- and middle-income countries. For this work, the research team won top honors from the Clinical Research Forum in 2024. Two analyses published in 2024 using data from that trial, the Azithromycin Prevention in Labor Use Study (A-PLUS), assessed possible additional benefits of this strategy to prevent infections, which account for approximately 11% of maternal deaths worldwide. One of the two recent studies showed that any maternal infection, including sepsis, abscesses, and wound infections, occurred 29% less often when the drug was administered during labor. The second study, which modeled the benefits and costs of intrapartum azithromycin, showed a reduction in hospital readmissions, unplanned clinical visits, and use of additional antibiotics. Using the average health-care costs across the study's eight clinical sites, the savings was estimated at $32,661 per 100,000 pregnancies. STRENGTHENING THE PATIENT VOICE Patients are at the heart of the FNIH mission, and their voices are incorporated into our research programs. People with lived experiences, patient advocacy groups, and care providers are vital to our work, helping to ensure that our programs look holistically at the impact our research will have on health and well-being. The FNIH's patient engagement strategy - including the Patient Ambassadors and Patient Engagement Council - reflects our commitment to ensuring patient voices guide our work. Their insights are essential to shaping impactful, forward-looking research programs. |
| Form 990, Part III, Line 4b Program Service Description | PROGRAM TWO - AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS - POWERING SCIENCE: 2024 FNIH AWARDS THE LURIE PRIZE IN BIOMEDICAL SCIENCES The Lurie Prize recognized outstanding achievement by promising scientists aged 52 years old or younger. The award included a $100,000 honorarium. PAUL-GALLIN TRAILBLAZER PRIZE FOR PHYSICIAN-SCIENTISTS The Paul-Gallin Trailblazer Prize recognizes the outstanding contributions of early- to mid-career physician-scientists whose research translates basic discoveries into novel approaches for diagnosing, preventing, treating, or curing disease and disability. The award includes a $100,000 honorarium. CHARLES A. SANDERS, MD, PARTNERSHIP AWARD We recognize our partners and their contributions through the annual Charles A. Sanders, MD, Partnership Award. This prize recognizes persons and/or organizations that have made significant contributions to our work in creating, implementing, and nurturing public-private partnerships that build bridges to breakthroughs in improved therapeutics, diagnostics, and potential cures. KOVLER PRIZE FOR TRUST IN LIFE SCIENCE JOURNALISM The Kovler Prize, which debuted in 2024 and carries a $25,000 honorarium, recognizes individual reporters who make complex health- and science-related topics digestible for the public. EVENTS AND EDUCATION In collaboration with the NIH and generous donors and partners, the FNIH manages training initiatives that offer educational opportunities to science students, ranging from high school to post-doctoral scholars, crossing boundaries and cultures. They learn through intensive training, collaborative engagement, mentoring, and hands-on research. Legacy funds from individual benefactors and foundations help move scientific achievement farther, faster, and give hope to future patients. Individual programs provide financial support, mentoring, and recognition to promising young scientists. Here is a just a sample of how the FNIH and its supporters power science: - The Deeda Blair Research Initiative for Disorders of the Brain awarded in 2024 three promising early-career physician-scientists with bold approaches to address mental illness. Each awardee received $200,000. This initiative was established by Mrs. William McCormick Blair, Jr., a member of the FNIH Board of Directors. - The Medical Research Scholars Program is a one-year intensive training program on the NIH campus offering medical, dental, and veterinary students opportunities to become engaged in research early in their careers. The FNIH has supported a total of 572 scholars since the program was established. - The FNIH promotes emerging research from up-and-coming scientists through annual lectures co-sponsored by the National Eye Institute, the National Institute of Neurological Disorders and Stroke, the National Institute of Allergy and Infectious Diseases, the National Center for Complementary and Integrative Health, and elsewhere. - For a complete list of all the ways the FNIH is powering science, go to the FNIH website. |
| Form 990, Part VI, Line 15a & 15b - Process to Establish Compensation | The Compensation Committee of the Board reviewed and concurred with the CEO's decisions establishing and adjusting the senior executive team's annual salaries and related compensation decisions. The Compensation Committee also approved the compensation level of the CEO and related compensation decisions. This process is undertaken annually. |
| Form 990, Part VI, Line 1a Delegate broad authority to a committee | The Board has an Executive Committee, which can make decisions on behalf of the Board (with some exceptions) between board meetings. |
| Form 990, Part VI, Line 11b Review of form 990 by governing body | The Form 990 is prepared and reviewed by an independent accounting firm. Prior to the submission of the Foundation for NIH's Form 990 to the Internal Revenue Service, each voting member of the board of directors shall be provided with a copy of the draft Form 990 as approved by the Chief Financial Officer. |
| Form 990, Part VI, Line 12c Conflict of interest policy | Directors, officers and employees are required to annually sign a statement which affirms that they have: - Received a copy of the conflict of interest policy - Read, understood and agreed to comply with the policy - Received and reviewed a listing of corporate and foundation donors, contractors, vendors, grantees, principal investigators and financial institutions with whom the FNIH has a current relationship - No actual or apparent conflicts of interest other than those disclosed in the statement. They must also make certain notifications in particular circumstances. The conflict of interest policy also has mechanisms for handling such conflicts. |
| Form 990, Part VI, Line 19 Required documents available to the public | All such documents are available upon request. In addition, the governing documents and financial statements are available on the FNIH website. |
| Form 990, Part X, Column (B) Cash & Investments | Approximately $122 Million of FNIH's Cash and Investments are invested in high quality short-term fixed income securities which are committed to FNIH's restricted assets. |
| Form 990, Part XI, Line 9 Other changes in net assets or fund balances | Refund of Prior Year Grants - 654801; Total - 654801; |
Schedule R IRS990ScheduleR
Id Disregarded Entities IdDisregardedEntitiesGrp
Disregarded Entity Name DisregardedEntityName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Health Data Access Authority LLC | BusinessNameLine1Txt |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 11400 Rockville Pike | AddressLine1Txt |
| Address Line2 | Suite 600 | AddressLine2Txt |
| City | North Bethesda | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 20852 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 333779122 | EIN |
| Primary Activities | To further the exempt purposes of the Foundation for the National Institutes of Health | PrimaryActivitiesTxt |
| Legal Domicile State | MD | LegalDomicileStateCd |
| Total Income | $0 | TotalIncomeAmt |
| End Of Year Assets | $0 | EndOfYearAssetsAmt |
Direct Controlling Entity Name DirectControllingEntityName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Foundation for the National Institutes of Health Inc | BusinessNameLine1Txt |